Anzeige
Mehr »
Sonntag, 26.10.2025 - Börsentäglich über 12.000 News
Das nächste Lila Sciences? Telescope Innovations ist das 30-Millionen-Dollar-Tor zu KI-gesteuerter Chemie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40H89 | ISIN: SE0022447348 | Ticker-Symbol: 1NP1
Frankfurt
24.10.25 | 08:01
3,600 Euro
+0,98 % +0,035
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
FLERIE AB Chart 1 Jahr
5-Tage-Chart
FLERIE AB 5-Tage-Chart
RealtimeGeldBriefZeit
3,6303,79525.10.
GlobeNewswire (Europe)
123 Leser
Artikel bewerten:
(0)

Toleranzia AB: Toleranzia applies for delisting of the Company's shares from Nasdaq First North Growth Market, conditional upon completion of the merger with Flerie

Toleranzia AB (publ) ("Toleranzia" or the "Company") has today, in connection with the upcoming merger between Toleranzia and Flerie (the "Merger"), which was announced through a press release on 25 March 2025, submitted an application for delisting of the Company's shares from Nasdaq First North Growth Market. The delisting is conditional upon the completion of the Merger.

The Merger is expected to be registered with the Swedish Companies Registration Office (Bolagsverket) on 19 August 2025, and the last day of trading in Toleranzia's shares is therefore expected to be 18 August 2025. Upon registration of the Merger with the Swedish Companies Registration Office, Toleranzia will be dissolved and its assets and liabilities transferred to Flerie, thereby completing the Merger.

Further information regarding the detailed timeline for delivery of shares in Flerie as merger consideration to the shareholders of Toleranzia will be communicated by Flerie and Toleranzia in due course.

For further information, please contact:
Charlotte Fribert - CEO, Toleranzia
Tel: +46 763 19 98 98
Email: charlotte.fribert@toleranzia.com

About Toleranzia AB (publ)
Toleranzia AB (publ) develops medicines that harness the power of the immune system to treat rare autoimmune diseases. The drugs, which target the cause of the disease, can cure or significantly alleviate the disease and not, like current treatments, just reduce symptoms. They have the potential to be the first long-acting or curative treatments that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. Toleranzia's shares are listed on Nasdaq First North Growth Market and Svensk Kapitalmarknadsgranskning AB, +46 (0)8 913 008, ca@skmg.se, is the company's Certified Adviser.

© 2025 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.